Biljana Beretich, MD
Neurology · Scarborough, MENPI 1609915602
Payments from drug & device makers
What this record shows
This record is dominated by education: $50 of the $68 with a category attached, or 73.1%. Genentech, Inc. accounts for 70.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2020 at $48 and has fallen 62.0% since, to $18 in 2025. That places this record below the midpoint for neurology clinicians in ME, where the typical reported total is $180.
Across 4 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$48
- TG Therapeutics, Inc.$18
- Travere Therapeutics, Inc.$2
Across 106 payments — averaging $6596.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$665K
- EMD Serono, Inc.$20K
- Biogen$13K
- Novartis$1K
What the payments were for
- Food & beverage$1827%
- Education$5073%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $48 |
| TG Therapeutics, Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 2 | $2 |
How this compares
$68 in reported general payments places this provider in the 35th percentile of 69 neurology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RebifInterferon Beta-1a/Albumin | 20 | $242,685 |
| Kesimpta PenOfatumumab | 26 | $221,001 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 17 | $187,627 |
| CopaxoneGlatiramer Acetate | 26 | $165,706 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 13 | $130,962 |
| TecfideraDimethyl Fumarate | 12 | $111,521 |
| AmpyraDalfampridine | 12 | $50,954 |
| Dalfampridine ErDalfampridine | 87 | $45,495 |
| Glatiramer Acetate | 12 | $16,654 |
| Mycophenolate Mofetil | 34 | $12,118 |
| Teriflunomide | 35 | $8,492 |
| Emgality SyringeGalcanezumab-Gnlm | 11 | $7,918 |
| Sumatriptan Succinate | 14 | $1,982 |
| Baclofen | 115 | $1,770 |
| Levetiracetam | 31 | $1,536 |
Paid to pharmacies, not to this prescriber.
Other neurology in Scarborough
- Heidi HenningerScarborough$350K
- Helia MaghziScarborough$37K
- Edward DrasbyScarborough$22K
- Christine Lu-EmersonScarborough$4K
- Dustin SmythScarborough$1K
- Jacob StoutScarborough$685
- Paul MuscatScarborough$471
- Tamara SchwartzScarborough$231
- Eric DinnersteinScarborough$197
- Diana GoodmanScarborough$180
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.